[go: up one dir, main page]

Silverstone, 1986 - Google Patents

Generalised allergic reaction to human insulin

Silverstone, 1986

View PDF
Document ID
17732597098143095399
Author
Silverstone P
Publication year
Publication venue
British Medical Journal (Clinical research ed.)

External Links

Snippet

Discussion The vaccination programme carned out in the United Kingdom has not yet eliminated congenital rubella, and therapeutic abortion on the grounds of detection ofmaternal rubella specific IgM remains the most practical, though not always the most …
Continue reading at pmc.ncbi.nlm.nih.gov (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/569—Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Similar Documents

Publication Publication Date Title
Gubler et al. Viraemia in patients with naturally acquired dengue infection
Gammon et al. Urticarial vasculitis: report of a case and review of the literature
Peaston et al. Metabolic studies and clinical observations during L-dopa treatment of Parkinson's disease
Vegezzi et al. Acute myelitis and ChAdOx1 nCoV-19 vaccine: casual or causal association?
EP0181364A1 (en) Compositions for the alleviation, treatment and diagnosis of arthritic disease and related conditions.
Park et al. Five cases of ocular toxocariasis confirmed by serology
Terry et al. First trimester prenatal diagnosis of congenital rubella: a laboratory investigation.
JP2005503533A (en) Osteoporosis diagnosis method and treatment method
Mylonas Borreliosis during pregnancy: a risk for the unborn child?
BAHN et al. Retroocular fibroblasts: important effector cells in Graves' ophthalmopathy
Koren et al. Serum concentrations, efficacy, and safety of a new, intravenously administered varicella zoster immune globulin in pregnant women
Peters et al. Progressive multifocal leukoencephalopathy: immunofluorescent demonstration of simian virus 40 antigen in CSF cells and response to cytarabine therapy
Rosenberg et al. Vegetating iododerma: an immunologic mechanism
Silverstone Generalised allergic reaction to human insulin
Mitchell et al. Chronic rubella vaccine-associated arthropathy
Rinieris et al. Free-thyroxine index in schizophrenic patients before and after neuroleptic treatment
Irsan et al. Evaluation of Humoral Response of Emergency Unit Healthcare Workers after Third Dose of COVID-19 Vaccination
Harrington et al. Incomplete transverse myelitis following rabies duck embryo vaccination
WO2024255011A1 (en) New use of compound salvia miltiorrhiza preparation
Bahn et al. Role of connective tissue autoimmunity in Graves' ophthalmopathy
Belec et al. Coxiella burnetii infection among subjects infected with HIV type 1 in the Central African Republic
EP0335726A2 (en) Use of thymopentin and derivatives in treatment of HIV viremic patients
Sabin et al. Clinically apparent and inapparent infection with Japanese B encephalitis virus in Shanghai and Tientsin
FRANSEN et al. A comparison of single-dose spectinomycin with five days of trimethoprim-sulfamethoxazole for the treatment of chancroid
Kuncl et al. Chronic human colchicine myopathy and neuropathy